SUMO-1 CRISPR Knockout and Activation Products (h)

SUMO-1 CRISPR Knockout and Activation Plasmids (h) designed to edit, knockdown or upregulate human SUMO-1 gene expression

Frontiers The E3 Ligase PIAS1 Regulates p53 Sumoylation to Control Stress-Induced Apoptosis of Lens Epithelial Cells Through the Proapoptotic Regulator Bax

Biomolecules, Free Full-Text

Genome Engineering: Genome Editing with CRISPR-Cas9 Leaders in Pharmaceutical Business Intelligence (LPBI) Group

CRISPR/Cas9-engineered mesenchymal stromal/stem cells and their extracellular vesicles: A new approach to overcoming cell therapy limitations - ScienceDirect

Molecules, Free Full-Text

IJMS, Free Full-Text

Alternative CRISPR Discovered @MIT Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Crosstalk between SUMOylation and ubiquitylation controls DNA end resection by maintaining MRE11 homeostasis on chromatin

The SUMO–NIP45 pathway processes toxic DNA catenanes to prevent mitotic failure

Frontiers SUMO and SUMOylation Pathway at the Forefront of Host Immune Response

Alternative splicing of the SUMO1/2/3 transcripts affects cellular SUMOylation and produces functionally distinct SUMO protein isoforms

Sumoylation of Cas9 at lysine 848 regulates protein stability and DNA binding

The Many Faces of Histidine Triad Nucleotide Binding Protein 1 (HINT1)

Immunohistochemical analyses of SUMO-1 (A, B, E, and F) and SUMO-2/3

Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing